SOPHiA GENETICS SA Files Form 4 for Ownership Changes

TL;DR

SOPHIA GENETICS SA filed a Form 4 on 4/3/26 for ownership changes.

AI Summary

On April 3, 2026, SOPHiA GENETICS SA filed a Form 4, reporting changes in beneficial ownership of securities. The filing pertains to the period of report ending April 2, 2026. The issuer, SOPHiA GENETICS SA, is located at LA PIECE, CH-1180 ROLLE V8 00000.

Why It Matters

Form 4 filings indicate potential shifts in insider holdings, which can signal confidence or changes in strategy for SOPHiA GENETICS SA.

Risk Assessment

Risk Level: low — This filing is a standard disclosure of ownership changes and does not inherently indicate significant risk.

Key Players & Entities

• SOPHiA GENETICS SA (company) — Issuer
• 0001840706 (company) — Issuer CIK
• 2026-04-03 (date) — Filing Date
• 2026-04-02 (date) — Period of Report
• CARDOZA GEORGE (person) — Reporting Person
• 0001518734 (person) — Reporting Person CIK

FAQ

Filing Documents

• wk-form4_1775213940.html (4)
• wk-form4_1775213940.xml (4) — 6KB
• 0001840706-26-000086.txt ( ) — 7KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * CARDOZA GEORGE (Last) (First) (Middle) C/O SOPHIA GENETICS INC. 401 PARK DRIVE, FLOOR 5 (Street) BOSTON MASSACHUSETTS 02215 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol SOPHiA GENETICS SA [ SOPH ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Financial Officer 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 04/02/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 04/02/2026 A 112,936 (1) A $ 0 112,936 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Share Option (Right to Buy) $ 5.04 04/02/2026 A 164,671 (2) 04/02/2036 Ordinary Shares 164,671 $ 0 164,671 D Explanation of Responses: 1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. 2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030. Remarks: /s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza 04/03/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR